ARPQ | Before treatment | 24 h after 1 st dose | 24 h after 2 nd dose | 48 h after 2 nd dose |
Fever | 88.7% (55/62) | 29.0% (18/62) | 1.6% (1/62) | NR |
Headache | 87.1% (54/62) | 48.4% (30/62) | 1.6% (1/62) | 1.6% (1/62) |
Nausea | 29.0% (18/62) | 3.2% (2/62) | NR | NR |
Stomach pain | 1.6% (1/62) | NR | NR | NR |
Vomiting | 1.6% (1/62) | NR | NR | NR |
Dizziness | 27.4% (17/62) | 3.2% (2/62) | NR | NR |
Tiredness | 61.3% (38/62) | 25.8% (16/62) | 3.2% (2/62) | 1.6% (1/62) |
Anorexia | 43.5% (27/62) | 9.7% (6/62) | 1.6% (1/62) | 1.6% (1/62) |
ASAQ | Before treatment | 24 h after1 st dose | 24 h after 2 nd dose | 24 h after 3 rd dose |
Fever | 82.5% (52/63) | 20.6% (13/63) | 3.2% (2/63) | NR |
Headache | 95.2% (60/63) | 46.0% (29/63) | 3.2% (2/63) | NR |
Nausea | 41.3% (26/63) | 19.0% (12/63) | 1.6% (1/63) | NR |
Stomach pain | NR | NR | NR | NR |
Vomiting | 3.2% (2/63) | 3.2% (2/63) | NR | NR |
Dizziness | 25.4% (16/63) | 3.2% (2/63) | NR | NR |
Tiredness | 69.8% (44/63) | 30.2% (19/63) | 3.2% (2/63) | NR |
Anorexia | 46.0% (29/63) | 20.6% (13/63) | NR | NR |